ADVERTISEMENT

Alembic Pharma Q2 Results Review - Miss On Operating Performance: Dolat Capital

The brokerage believes H2 will be better with recovery in sales aided by ramp-up in new launches and stable price erosion in the US, recovery in domestic and RoW markets.

<div class="paragraphs"><p>Colorful pills. (Source: freepik)</p></div>
Colorful pills. (Source: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More